Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
June 21, 2004
- 30% Copayment Rate Affecting Medical Visits: Korosho Survey
June 21, 2004
- NEW PRODUCTS
June 21, 2004
- Members of Patient Groups Show Strong Dissatisfaction with Physicians: OPIR Survey
June 21, 2004
- To Aggressively Increase Deals with Top 10 Makers: Mr Bessho of Suzuken
June 21, 2004
- PRESS SEMINAR
June 21, 2004
- Ethical Drug Market Grows 3.6% to \7.97 Trillion in FY2003: IMS Japan
June 21, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 21, 2004
- BUSINESS NEWS IN BRIEF
June 14, 2004
- New NHI Drug Pricing Needs Further Reform: Dr Hayakawa
June 14, 2004
- Korosho Explains Japan-EU Mutual GMP Recognition System
June 14, 2004
- REGULATORY NEWS IN BRIEF
June 14, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 14, 2004
- Research on Iressa Progressing at the Gene Level
June 14, 2004
- Bezafibrate Inhibits Onset of Diabetes Mellitus: Kissei
June 14, 2004
- 26 Listed Makers Report 0.6% Decline in Consolidated Sales: Survey
June 14, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
June 14, 2004
- WORLD NEWS IN BRIEF
June 14, 2004
- OTC NEWS IN BRIEF
June 14, 2004
- Listed Makers Report Decline in Sales, Strong Increase in Net Profits on Non-consolidated Basis
June 14, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…